23 results about "Sodium Deoxycholate" patented technology

The application provides a topical traditional Chinese medicine composition for treating vulvar leukoplakia and a preparation method thereof. The composition is composed of traditional Chinese medicinal materials such as angelica, cortex psoraleae and barks of dictamnus dasycarpus, and a penetration enhancer, an activating agent and a moisturizing agent. The penetration enhancer is composed of soybean lecithin, phosphatidylethanolamine and cholesterol, the activating agent is sodium cholate, sodium deoxycholate and sodium taurocholate, and the moisturizing agent is eucalyptus oil. The drugs are compatible to exert the effects of clearing heat and drying dampness, cooling blood and nourishing yin, activating blood and resolving stasis, warming yang and dispelling cold and supporting healthy qi and tonifying the body resistance. The traditional Chinese medicine composition is prepared through supercritical extraction, micronization treatment, solution preparation and intermittent ultrasonic homogenization. The traditional Chinese medicinal materials are used for treating the etiology, pathogenesis and symptoms of vulvar leukoplakia, the penetration enhancer reduces the skin barrier function, the activating agent enhances the drug activity and permeability, and the moisturizing agent maintains the skin moisture and assists in anti-inflammation. The clinical application effectively relieves the symptoms of patients with vulvar leukoplakia, improves the pathological state of local skin and improves the treatment effect, thereby providing a new effective option for the treatment of vulvar leukoplakia.

The application provides a preparation method and application of a near-infrared two-region fluorescent sensor, and chiral single-walled carbon nanotubes are separated by using a double water phase extraction method; materials in the separation process include deionized water, polyethylene glycol, dextran, sodium dodecyl sulfate, sodium deoxycholate and cholic acid sodium hydrate; the chiral single-walled carbon nanotubes are dispersed and mixed with 4-nitrobenzene tetrafluoroboric acid diazonium salt to obtain the fluorescent sensor; high-purity (6,5)-SWCNT is efficiently and simply separated by using the double water phase extraction technology, the prepared SWCNT-NBD nanomaterial has good optical performance, including bright light emission in the near-infrared two-region, has good penetration capacity on biological tissues, the fluorescent detector (SWCNT-NBD) has low detection line, wide linear range, good selectivity on DA, and is convenient to prepare and low in cost.

Disclosed are a pharmaceutical composition, an aprepitant injection, and an aprepitant freeze-dried powder injection. The pharmaceutical composition comprises aprepitant, a primary stabilizer, and a secondary stabilizer, wherein the primary stabilizer comprises sodium deoxycholate and the secondary stabilizer comprises povidone. The aprepitant injection can be administered by injecting. The formulation uses a largely reduced amount of excipients, and is less irritative to an injection site, less prone to cause a hypersensitive reaction, and thus safer when being used by a patient. The formulation has good stability and can be stored and transported at room temperature, largely reducing production, storage, and transportation costs.

This invention relates to a midazolam nanocrystal suspension, which, by weight-volume percentage, comprises 5%–45% midazolam, 1%–10% Tween, and 0.1%–10% sodium deoxycholate (SDC). The midazolam nanocrystal suspension of this invention exhibits superior blood-brain barrier permeability and bioavailability, making it suitable for needle-free injection administration.

The invention discloses a brain-targeted nasal-spray amphotericin B phospholipid complex and a preparation method and application thereof, and belongs to the technical field of pharmaceutical preparations, the brain-targeted nasal-spray amphotericin B phospholipid complex is prepared by adopting a film dispersion method, and the preparation method comprises the following steps: dissolving 15-hydroxystearic acid polyethylene glycol ester, phospholipid, cholesterol, amphotericin B and optional other auxiliary components in a solvent, removing the solvent until a film is formed, and drying to obtain the brain-targeted nasal-spray amphotericin B phospholipid complex. And carrying out hydration dispersion to obtain the amphotericin B-loaded phospholipid complex. According to the amphotericin B sodium deoxycholate injection, the problems that the traditional amphotericin B sodium deoxycholate injection is high in renal toxicity, the intrathecal injection is poor in solubility, and low in bioavailability and patient compliance, large in side effect and the like due to the fact that the traditional amphotericin B sodium deoxycholate injection is difficult to penetrate through a blood brain After nasal administration, the drug is quickly delivered into the brain, so that the slow release of the drug is realized, the intracerebral bioavailability of the drug is improved, high brain targeting and low systemic toxic and side effects are realized, and good clinical application value and market prospect are achieved.

The application discloses a kind of DOC-Chaps synergistic core's clinical and animal tissue rapid transparent reagent and three-dimensional imaging method. Rapid transparent reagent is mainly dissolved in deionized water by sodium deoxycholate (DOC), 3-[(3-cholamide propyl) dimethylamino]-1-propane sulfonic acid (Chaps), urea and 1-methylimidazole; DOC efficiently dissolves high-density lipid, Chaps gently destroys membrane structure, both complement each other, realize lipid rapid, depth clearance and significantly reduce light scattering; urea loosens collagen fiber and protein aggregate, improves the penetration rate of reagent; 1-methylimidazole selectively removes hemoglobin, reduces light absorption. The transparent reagent of the application can make millimeter thick brain slices in 4 (mouse brain) / 6 (human brain) hours The light transmittance of specific wavelength is greater than or equal to 90%, and there is no obvious tissue shrinkage / expansion, the compatibility of fluorescent protein and antibody label is excellent, suitable for three-dimensional imaging of high-lipid, high-hemoglobin samples such as in-vitro human brain, kidney, liver and mouse brain, heart, kidney, liver, intestinal tract, embryo, etc.

The application discloses a clinical biochemical composite quality control product, which comprises detection item raw materials, a matrix liquid and a protective agent; the detection item raw materials are alkaline phosphatase, amylase, sodium glycocholate, cholinesterase, creatinine, leucine aminopeptidase, lactate dehydrogenase, lipase, triglyceride, cholesterol, uric acid, urea, alanine aminotransferase, aspartate aminotransferase, gamma-glutamyl transferase, glucose, alpha-hydroxybutyric acid dehydrogenase, sodium hydrogen phosphate, magnesium chloride, calcium chloride, ferrous chloride, bilirubin, pancreatic amylase and sodium bicarbonate; the matrix liquid is bovine serum albumin and human serum albumin; and the protective agent is dithiothreitol (DTT), mannitol, trehalose, sodium chloride, a composite enzyme stabilizer AES and sodium azide. The quality control product can realize the detection of 27 clinical biochemical items, and the freeze-drying process is adopted, so that the freeze-dried composite quality control product has low viscosity, is easy to be re-dissolved and mixed, has high stability and has small matrix effect.

A composition comprising a glucagon-like peptide 1 (GLP-1) agonist for sublingual or buccal administration, wherein the composition comprises one or more agents selected from the group consisting of; sodium glycodeoxycholate; sodium deoxycholate; carboxymethyl cellulose; sodium alginate; SNAC (salcaprozate sodium); a non-ionic ester alkoxylate (or alkanoic acid ester alkoxylate); and soy lecithin.

The application provides a method for improving the linear range of a latex-enhanced turbidimetry kit and the latex-enhanced turbidimetry kit, and relates to the technical field of analysis and detection. The application finds that sodium deoxycholate is added to reagent 1 of the existing latex-enhanced turbidimetry kit. Experimental verification shows that the correlation coefficient of the existing latex-enhanced turbidimetry kit can be effectively improved, and the upper limit of the detection linearity of the latex-enhanced turbidimetry kit is improved to 500 mg / L, thereby effectively alleviating the problem that the linear range of the reagent of the existing latex-enhanced turbidimetry kit is narrow, and 90% of the sample amount in the clinic cannot be covered, so as to affect the accuracy of the clinical detection result.

The application discloses a pharmaceutical composition, an aprepitant injection and an aprepitant freeze-dried powder injection. The pharmaceutical composition comprises aprepitant, a primary stabilizer and a secondary stabilizer, wherein the primary stabilizer comprises sodium deoxycholate, and the secondary stabilizer comprises povidone. The aprepitant injection provided by the application can be injected for administration, the dosage of auxiliary materials is greatly reduced, the injection site is less irritating when used by patients, and the aprepitant injection is less likely to cause hypersensitivity reaction and is safer; the preparation has good stability, can be stored and transported at room temperature, and greatly reduces the production, storage and transportation costs.

The application discloses a metal organic framework material with a hollow structure and a preparation method and application thereof. The preparation method comprises the following steps: dissolving sodium deoxycholate in a buffer solution to form solution A, dissolving zinc nitrate hexahydrate in water to form solution B, stirring solution A in a water bath, then adding solution B to continue stirring, obtaining solution C after separation and dispersion, adding an organic ligand to solution C to react, and centrifuging, washing and drying the product to obtain the metal organic framework material with the hollow structure. The method has the advantages of simple operation, easy process control, high economy, wide popularization, fast transmission quality of the prepared MOFs material, high porosity, rich active components, more exposed active sites, good compatibility to harsh conditions, and wide application prospects in the fields of separation, sensing, catalysis, drug release and energy.

The application discloses a composition with the effect of auxiliary treatment of arthritis and a preparation method and application thereof, and the composition comprises the following preparation raw materials in parts by weight: non-denatured type II collagen 5-15 parts, curcuma longa extract 56.8-100 parts, frankincense extract 18.7-39.8 parts, sophora flower bud extract 15-28.5 parts, chondroitin sulfate 20-30 parts, glyceryl behenate 15-25 parts, chitosan 3-7.5 parts, sodium deoxycholate 3-8 parts, polyethylene glycol-15 hydroxystearate 5-15 parts, anti-knotting agent 1-3 parts, curing agent 5-15 parts and filling agent 15-25 parts. The application can treat arthritis through the trinity of immune-mechanical-metabolic pathways, and the effect is remarkable and fast, and has a certain residual effect.

This invention belongs to the field of cosmetic technology, specifically relating to an essential oil for promoting skin regeneration and its preparation method. By weight, it comprises the following components: 50-60 parts rosehip oil, 6-8 parts lavender essential oil, 8-10 parts rose essential oil, 4-6 parts modified polyaspartic acid penetration enhancer, and 1-3 parts stearyl alcohol-modified recombinant collagen flexible liposomes. In this invention, recombinant collagen is encapsulated in liposomes, and sodium deoxycholate is added during the liposome preparation process. The liposomes encapsulating the recombinant collagen deform as they pass through the intercellular channels of skin cells, adapting to the size of the intercellular channels, thereby improving the absorption of the recombinant collagen and enabling it to reach the dermis, promoting collagen production in the dermis and thus promoting skin regeneration.

A formulation for nutraceutical and / or pharmaceutical use based on protein nanoparticles is described, including a bioactive compound chosen from hydroxytyrosol, tyrosol, olive phenolic compounds, and mixtures thereof, and a zein protein matrix stabilized with sodium deoxycholate.

The application belongs to the technical field of in vitro diagnostic reagents, and discloses a cleaning solution for acridinium ester chemiluminescence immunoassay of allergens, a preparation method and application thereof. The cleaning solution is composed of HEPES buffer, a triple surfactant system (poloxamer 188, sodium deoxycholate and octyldecyl glucoside), glycerol, PEG8000, disodium EDTA and a composite preservative of Proclin 950 and BHT. The triple surfactant synergistic system is adopted to reduce non-specific adsorption, the HEPES weak alkaline buffer system avoids the inhibition of phosphates on acridinium ester luminescence, and the composite preservative system solves the toxicity and stability problems of traditional preservatives. The cleaning solution can significantly reduce the background luminescence value, the inhibition rate of hemolysis / lipemia / jaundice interference is less than 5%, the detection accuracy deviation is within ±5% (r>0.99), the precision is less than 3.5%, and the room temperature stability is more than 13 months, and the comprehensive performance is better than that of the commercially available products.

The invention provides a lipase detection kit, application and a lipase detection method. The detection kit comprises a first solvent, a second solvent and a substrate, the first solvent comprises a disodium hydrogen phosphate buffer solution, tartaric acid and sodium deoxycholate, the pH value of the first solvent is 7.0-9.0, the concentration of the disodium hydrogen phosphate buffer solution is 0.11-0.28 moL / L, and the dosage of the sodium deoxycholate is also limited; the second solvent comprises dimethyl sulfoxide; according to the present invention, the substrate is 1, 2-di-O-lauroyl-racemic-glycerol-3-(glutaric acid 6-methyl resorufin ester), and the above kit can be used for detecting lipase, can easily improve the stability of the substrate 1, 2-di-O-lauroyl-racemic-glycerol-3-(glutaric acid 6-methyl resorufin ester), can easily expose the active center of lipase, and can be used for detecting lipase. And the accuracy of a detection result is improved.

The invention discloses a special high-concentration lysate for exosome protein extraction, and belongs to the technical field of exosome lysate. The reagent is mainly prepared by mixing a reagent SDS (Sodium Dodecyl Sulfate), NP-40, sodium deoxycholate, TritonX-100 and NaCl. The specific preparation method comprises the following steps: taking 10ml of 50mM. Tris-HCl buffer solution, adding 1g. SDS, 1g. NP-40, 0.1 g of sodium deoxycholate, 100. Mu l. TritonX-100 and 0.58 g. NaCl, and fully blowing, beating and uniformly mixing. A subversive exosome protein extraction solution is provided by organically integrating the two functional modules of'mild splitting 'and'synchronous concentration' into a whole. According to the formula of the lysate, exosomes can be mildly and specifically lysed under the condition that the concentration of effective components is extremely high, and the integrity of key membrane proteins such as CD9, CD63 and CD81 is perfectly protected; meanwhile, due to the built-in concentration capacity, a high-concentration protein sample can be obtained without relying on tedious steps such as super-separation in the cracking process. The special high-concentration lysate for exosome protein extraction achieves the effect of improving the efficiency and yield of exosome protein extraction.

The invention discloses lipid vesicles co-loading salvia miltiorrhiza-radix puerariae effective components, a preparation method and application, and the preparation method comprises the following steps: placing egg yolk lecithin, sodium deoxycholate, radix puerariae isoflavone, tanshinone and salvianolic acid in a round-bottom flask according to a weight ratio of 50: (22-27): 10: (0.3-0.9): 7, then adding methanol for fully dissolving, carrying out rotary evaporation under the conditions of 40 DEG C and 50 rpm / min, filtering, washing, and drying to obtain the lipid vesicles. Removing methanol to obtain a film; performing vacuum drying overnight at room temperature to obtain a dry and transparent film framework; adding ultrapure water into the membrane skeleton, and carrying out hydration treatment to obtain a liposome solution; and filtering the liposome solution with a 0.22 [mu] m cellulose acetate membrane to obtain the liposome. Through multi-component synergistic encapsulation, strong hydrophobic tanshinone is encapsulated in a phospholipid bilayer, weak hydrophobic pueraria isoflavone is distributed on a phospholipid layer or interface, and hydrophilic salvianolic acid is contained in a water phase or interface, so that the stability of a lipid vesicle system is enhanced, and the problem of low bioavailability of a preparation is solved.

The invention discloses emedastine fumarate eye drops and a preparation method thereof. The emedastine fumarate eye drops are prepared from the following raw materials: emedastine fumarate, hydrogenated lecithin, cholesterol, 7-dehydrocholesterol, sodium deoxycholate, polyethylene glycol, a chitosan derivative, poloxamer, a preservative, an isoosmotic adjusting agent, a buffer solution and water for injection. The emedastine fumarate eye drops are a system solution compounded by emedastine fumarate liposome, a nano structure and in-situ gel. The emedastine fumarate eye drops prepared by the invention can control the drug release, reduce the irritation, prolong the retention time of eyes, improve the drug availability and enhance the curative effect, so that the medication frequency or medication time is reduced, and the normal physiological environment of eyes is maintained.

The invention discloses an integrated cartilage decellularization kit and a decellularization method thereof, and belongs to the technical field of biomedicine. The kit comprises an independently packaged ready-to-use tissue lysis buffer solution and nucleic acid digestive enzyme dry powder mixture, the pH value of the ready-to-use tissue lysis buffer solution is 7.4-7.6, and every 100 mL of the ready-to-use tissue lysis buffer solution contains 0.9 g of sodium chloride, 0.05-0.2 g of sodium deoxycholate monohydrate, 0.05-0.2 g of calcium chloride dihydrate, 0.05-0.2 g of magnesium chloride hexahydrate and 0.4-0.6 mL of a surfactant. The nucleic acid digestive enzyme dry powder mixture is a mixture of DNase I dry powder and RNase A dry powder, and the mass ratio of the DNase I dry powder to the RNase A dry powder is 1: (0.4-0.6). The invention further discloses a decellularization method adopting the integrated cartilage decellularization kit. According to the invention, the decellularized cartilage scaffold which has low immunogenicity and highly retains natural extracellular matrix structure and biochemical composition can be stably prepared.

The present application belongs to the field of biotechnology, and particularly relates to a preparation method of pneumococcal capsular polysaccharide. The method comprises the following steps: (1) providing a pneumococcal fermentation broth, sterilizing and centrifuging the pneumococcal fermentation broth, collecting a first supernatant and ultrafiltering to obtain a first ultrafiltrate; (2) adding a neutral salt to the first ultrafiltrate, mixing in sodium deoxycholate to obtain a mixed solution, and adjusting the pH to 4.5-5.0; then centrifuging to collect a second supernatant; the ratio of the sodium deoxycholate to the first ultrafiltrate is 0.4-0.7 g:100 mL; (3) adjusting the pH of the second supernatant to neutral, precipitating impurities by calcium salt, centrifuging to collect a third supernatant; and then drying the third supernatant to obtain the pneumococcal capsular polysaccharide. The preparation method has the advantages of simple process, low cost, high recovery rate of pneumococcal capsular polysaccharide, easy scale-up, and suitability for industrial application.

The invention relates to the technical field of microbiological detection, and particularly discloses a culture medium for selectively separating and culturing Burkholderia cepacia, which comprises the following components: 8-12 g / L of tryptone, 8-12 g / L of sucrose, 1-2 g / L of yeast extract, 1-2 g / L of monopotassium phosphate, 5-10 g / L of sodium pyruvate, 4-7 g / L of sodium chloride, 15-23 mg / L of phenol red, 10-18 g / L of agar, 0.8-1.3 mg / L of crystal violet, 0.5-5 g / L of selective inhibitor, and the balance of water. 10-30 g / L of a specific accelerant and the balance of water; the selective inhibitor is selected from one or more of sodium deoxycholate, sodium taurocholate, sodium glycocholate and propyl gallate; the specific accelerant is lactose, cane sugar and vanillic acid; and the culture medium does not contain any antibiotic component. The culture medium disclosed by the invention is free of antibiotic components, good in selectivity and high in growth promoting ability, and has a very good market application prospect.

The invention discloses a rapid low-sample-consumption phosphoproteomics sample pretreatment kit, belongs to the field of sample pretreatment kits, and particularly relates to a sample pretreatment kit which comprises a protein extraction reagent A and a phosphopeptide enrichment reagent C, the protein extraction reagent A comprises at least one of ethyl phenyl polyethylene glycol, sodium deoxycholate and lauryl sodium sulfate, and the phosphopeptide enrichment reagent C comprises titanium dioxide. The content of the ethyl phenyl polyethylene glycol is 0.1-2wt%; or the content of the sodium deoxycholate is 0.1-1wt%; or the content of the lauryl sodium sulfate is 0.05-0.2 wt%. The invention discloses a phosphorylated proteomics sample pretreatment kit which is rapid, low in sample consumption, good in extraction effect and good in detection effect.